Biotech IV Monitor

CNTA — Centessa Pharmaceuticals plc

Acquired by Eli Lilly · June 2026
Centessa Pharmaceuticals plc was acquired by Eli Lilly in June 2026. CNTA no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Eli Lilly, and their dates may not have been updated since.

Clinical trial readout dates for Centessa Pharmaceuticals plc, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts21 Phase 3

Upcoming readouts

Phase 2 ORX750
Narcolepsy Type 1; Narcolepsy Type 2 · NCT06752668
December 2026
Recruiting
Phase 2/3 cleminorexton
Narcolepsy Type 1; Narcolepsy Type 2 · NCT07598708
September 2027
Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow CNTA, you can start the conversation.
Contact — questions or corrections about CNTA: dukeupt@gmail.com